Abstract
ObjectivePneumocystis jirovecii pneumonia (PJP) was reported among immunosuppressed patients with deficits in cell-mediated immunity and in patients treated with immunomodulatory drugs. The aim of this study was to identify risk-factors for PJP in noninfected HIV patients.MethodsThis retrospective, test negative, case-control study was conducted in six hospitals in Israel, 2006–2016. Cases were hospitalized HIV-negative patients with pneumonia diagnosed as PJP by bronchoalveolar lavage. Controls were similar patients negative for PJP.ResultsSeventy-six cases and 159 controls were identified. Median age was 63.7 years, 65% males, 34% had hematological malignancies, 11% inflammatory diseases, 47% used steroids and 9% received antilymphocyte monoclonal antibodies. PJP was independently associated with antilymphocyte monoclonal antibodies (OR 11.47, CI 1.50–87.74), high-dose steroid treatment (OR 4.39, CI 1.52–12.63), lymphopenia (OR 8.13, CI 2.48–26.60), low albumin (OR 0.15, CI 0.40–0.54) and low BMI (OR 0.80, CI 0.68–0.93).ConclusionIn conclusion, rituximab, which is prescribed for a wide variety of malignant and inflammatory disorders, was found to be significant risk-factor for PJP. Increased awareness of possible PJP infection in this patient population is warranted.
Highlights
Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection that mostly afflicts immunosuppressed patients with deficits in cell-mediated immunity [1]
Rituximab, which is prescribed for a wide variety of malignant and inflammatory disorders, was found to be significant risk-factor for PJP
In multivariate logistic regression analysis for risk factors (Table 2), PJP was independently associated with Rituximab use (OR 11.47 (95%CI 1.5–87.7), p = 0.019), high-dose steroid treatment (OR 4.39 (95%CI 1.52–12.66), p = 0.006), lymphopenia (OR 8.13 (95%CI 2.48–26.61), p = 0.001), low albumin (OR 0.15 (95%CI 0.04–0.54), p = 0.004) and low BMI (OR 0.80, p = 0.018)
Summary
Citation: Zalmanovich A, Ben-Ami R, Rahav G, Alon D, Moses A, Olshtain-Pops K, et al (2020) Rituximab identified as an independent risk factor for severe PJP: A case-control study. PLoS ONE 15 (9): e0239042. https://doi.org/10.1371/journal. pone.0239042 Editor: Minghua Wu, University of Texas McGowan Medical School at Houston, UNITED STATES Pneumocystis jirovecii pneumonia (PJP) was reported among immunosuppressed patients with deficits in cell-mediated immunity and in patients treated with immunomodulatory drugs. The aim of this study was to identify risk-factors for PJP in noninfected HIV patients.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
